



**Cosentyx**<sup>®</sup>  
(secukinumab)

# Billing & Coding Guide for the Intravenous (IV) Formulation of COSENTYX<sup>®</sup> (secukinumab)

A useful tool for navigating  
the reimbursement landscape.

**For additional support, reach out  
to your dedicated Access and  
Reimbursement Team Member  
or contact COSENTYX<sup>®</sup> Connect  
Patient Support**



**Phone:** 1-844-COSENTYX (1-844-267-3689)



**Fax:** 1-844-666-1366 or 1-800-343-9117



**Online:** [ReadySetCOSENTYX.com](http://ReadySetCOSENTYX.com)

**Please see Important Safety Information on pages 13 and 14.  
Please see full [Prescribing Information](#), including [Medication Guide](#).**

# Overview

**We know that navigating insurance and reimbursement can be a challenge.**

This guide is intended to provide an overview of coding and coverage information related to the IV formulation of COSENTYX<sup>®</sup> (secukinumab). Healthcare professionals (HCPs) can reference this guide, in addition to other resources, to determine for themselves the appropriate claims to file for the IV formulation of COSENTYX and related services. Novartis does not guarantee payment or coverage for any product or service.

Information specific to coding and billing is subject to change without notice and should be verified by the provider for each patient prior to treatment. It is always the provider's responsibility to determine the appropriate healthcare setting, and to submit true and correct claims for the products and services rendered. Providers should contact third-party health plans for specific information on their coding, coverage and payment policies, and fee schedules.



**Click** on any section to jump to that page

- This guide is interactive—keep an eye out for callouts to see where you can click
- Clickable purple terms used throughout this guide are defined in glossary

## Table of Contents

Basic coverage information.....	3
Drug codes.....	4
Current Procedural Terminology (CPT) codes.....	7
Potential ICD-10-CM diagnosis codes.....	8
Setting of care codes.....	9
Submitting claims: claim filing checklist.....	10
Submitting claims: sample forms.....	11
Indications & Important Safety Information .....	13
Glossary.....	15
COSENTYX <sup>®</sup> Connect Support Services.....	16

For questions or support, reach out to your Access and Reimbursement Team Member or COSENTYX<sup>®</sup> Connect Patient Support.



**Phone:** 1-844-COSENTYX (1-844-267-3689)



**Fax:** 1-844-666-1366 or 1-800-343-9117



**Online:** ReadySetCOSENTYX.com

*ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.*

# Basic coverage information

**Coding and billing requirements for the IV formulation of COSENTYX<sup>®</sup> (secukinumab) vary based on many factors, including the site of service where the drug is administered, the type of insurance the patient has, and the benefit under which the IV formulation of COSENTYX is covered.**

## Site of service

The IV formulation of COSENTYX is intended for use under the guidance and supervision of a physician. For most health plans, the site of service will affect the coding and billing requirements. This guide provides information on coverage, coding, and billing for the IV formulation of COSENTYX when administered in physicians' offices, hospital outpatient settings, and stand-alone infusion centers.

## Health plan type<sup>1</sup>

Coverage, as defined by each health plan type and benefit package, may vary depending on the site of service and the patient's status and medical history.

Medicare	Medicaid	Private health plans
<p>Medicare typically covers and separately reimburses drugs provided in the physician's office as well as most drugs provided in the hospital outpatient department that are not self-administered and are provided incident to a physician service.</p> <p>Coverage under Medicare Advantage can vary by plan. Providers should check with the patient's plan for specific coverage and payment information.</p>	<p>Medicaid coverage and payment can vary by state or by the specific managed Medicaid plan. Providers should check with the state program or plan for specific coverage information for all health plan types for fee schedules.</p>	<p>Private health plans may cover provider-administered treatments and the medical services associated with their administration. However, there may be restrictions on coverage, such as special requirements for distribution and precertification. Private health plans may also vary in the payment methods they use to reimburse the sites of service where the treatments are administered.</p>



Contact your Access and Reimbursement Team Member to better understand coverage for the IV formulation of COSENTYX.

Most health plans cover physician-administered products under a medical benefit rather than a pharmacy benefit. In the case of Medicare, provider-administered treatments will typically be covered under Part B. However, private health plans and Medicaid may require that physicians order the treatment through a specialty pharmacy. Specialty pharmacies may bill the health plan under the medical or pharmacy benefit, depending on what that plan requires. Additionally, Medicare Advantage health plans may cover the treatment in a similar way to private health plans depending on the benefit design of the patient.

**Reference: 1.** Tikkanen R, Osborn R, Mossialos E, Djordjevic A, Wharton GA. International health care system profiles: United States. Published June 5, 2020. Accessed June 26, 2023. <https://www.commonwealthfund.org/international-health-policy-center/countries/united-states>

# Drug codes

The table below provides common procedure and drug codes that may be related to administration of the IV formulation of COSENTYX<sup>®</sup> (secukinumab) in the physician office setting.

## National Drug Code (NDC)<sup>1</sup>

The **NDC** is a unique, 10-digit, 3-segment number. It is a universal product identifier for drugs in the United States present on all over-the-counter and prescription medication packages and inserts. Many NDC numbers listed on drug packaging are in 10-digit format.

An 11-digit NDC code may be derived from the 10-digit code. Many health plans require the use of the 11-digit code for proper billing.

Please note: Because many practice management systems automatically remove the hyphens, be sure that they are excluded from submission on the claim. Check with the patient's health insurance provider to determine sequence requirements.

Trade name	Drug strength and dose	10-digit NDC number	11-digit NDC number
COSENTYX	125 mg/5 mL (25 mg/mL) single-dose vial for dilution	0078-1168-61	00078-1168-61

When using miscellaneous codes, health plans may require additional information, such as the NDC, name of the drug, strength administered, etc.



Contact your Access and Reimbursement Team Member to better understand NDC codes for the IV formulation of COSENTYX.

**Reference:** 1. COSENTYX. Prescribing information. Novartis Pharmaceuticals Corp.

# Drug codes (cont)

## Healthcare Common Procedure Coding System (HCPCS) Level II code(s)<sup>1</sup>

**HCPCS** Level II codes are used to identify drugs, supplies, medical procedures, and other services. In the absence of a product-specific code, a not-otherwise-classified HCPCS code is required. Health plans may also require the NDC. HCPs should contact third-party health plans for specific information on their coding, coverage, and payment policies.

Not all codes are available at launch. A miscellaneous code is typically used until a permanent code is implemented. A product-specific code may be available within 6 to 9 months after approval depending on approval timing. The timeline for a product-specific code is determined by the Centers for Medicare & Medicaid Services (CMS). Once a product-specific code is assigned the unclassified codes shown below are no longer applicable.

HCPCS code	Descriptor	Setting of care	Billing unit
J3490	Unclassified drug	Physician's office, hospital outpatient setting, stand-alone infusion center	Bill 1 unit per infusion
J3590	Unclassified biologic	Physician's office, hospital outpatient setting, stand-alone infusion center	Bill 1 unit per infusion
C9399	Unclassified drug or biological	Only valid for Medicare on claims for hospital outpatient department services and procedures	Bill 1 unit per infusion

**When using miscellaneous codes, health plans may require additional information, such as the NDC, name of the drug, strength administered, etc.**

**Reference: 1.** Centers for Medicare & Medicaid Services. HCPCS quarterly update. Accessed July 27, 2023. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>

# Drug codes (cont)



[Click here](#) for dosage calculator

## Modifiers

Modifiers play a crucial role in coding and billing processes. They provide additional information about a service or procedure without changing its definition or code. By using modifiers, healthcare providers can indicate specific circumstances such as route of administration, wasted product, and more. To determine the applicability of a modifier, it is recommended to consult the relevant CMS manuals. [Check the Insurance Plan or Medicare Administrative Contractor to see if the JA modifier is needed for billing.](#)

Route of administration modifiers	
Modifier	Description
JA	Administered intravenously
JB	Administered subcutaneously

Wasted-product modifiers	
Modifier	Description
JZ	Zero drug amount discarded/not administered to any patient
JW	Drug amount discarded/not administered to any patient

The JZ modifier is an HCPCS Level II code used to report that no amount of drug was discarded and the claim is eligible for payment. The modifier should only be used for claims that bill single-dose container drugs such as COSENTYX<sup>®</sup> (secukinumab).<sup>1,2</sup> If there were any discarded amounts of COSENTYX, the JW modifier should be used. The JW modifier is designated for the discarded or unused portion of the drug.

- ▶ When billing COSENTYX using a miscellaneous J code, a unit of 1 is required on the billing line
- ▶ Discarded units are billed on another line using the JW modifier and also noted in additional information (Box 19 of the [CMS-1500](#)) or remarks (Box 80 of the [CMS1450/UB-04](#))

**References:** 1. Centers for Medicare & Medicaid Services. Medicare program discarded drugs and biologicals—JW modifier and JZ modifier policy. Accessed June 9, 2023. <https://www.cms.gov/medicare/medicare-fee-for-servicepayment/hospitaloutpatientpps/downloads/jw-modifier-faqs> 2. COSENTYX. Prescribing information. Novartis Pharmaceuticals Corp.



# Current Procedural Terminology (CPT) codes<sup>1</sup>

**CPT** codes are the most widely accepted codes for reporting medical procedures and services under government and private health plans. Below are the applicable codes that relate to the administration of COSENTYX<sup>®</sup> (secukinumab).

Type	Code	Description
CPT code*	96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
CPT code*	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

\*CPT © 2023 American Medical Association. All rights reserved.

**READY  
SET**  
COSENTYX



**We are here to help you help your patients.**

For additional support and resources, reach out to your Access and Reimbursement Team Member or visit [ReadySetCosentyx.com](https://www.ReadySetCosentyx.com).

**Reference: 1.** American Medical Association (AMA). *CPT Professional 2023 and E/M Companion 2023 Bundle*. AMA; 2023.

Please see Important Safety Information on page 13 and 14. Please see full Prescribing Information, including Medication Guide.

# Potential *ICD-10-CM* diagnosis codes

The codes listed are provided for educational purposes only and are not a guarantee of coverage or reimbursement. Coverage and reimbursement may vary significantly by health plan, patient, and setting of care. It is the sole responsibility of the HCP to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient. The codes included on the following pages are included as examples of potential codes that may be relevant for the IV formulation of COSENTYX<sup>®</sup> (secukinumab).

## **International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes<sup>1</sup>**

**ICD-10-CM** diagnosis codes identify why a patient may need treatment (eg, conditions, diseases, related health problems, abnormal findings) and document the medical necessity for a patient to receive treatment with COSENTYX. You should review the health plan's guidance to ensure appropriate codes are selected based on the patient's medical record.

Disease	Possible <i>ICD-10-CM</i> code	Descriptor
PsA	L40.50	Arthropathic psoriasis, unspecified*
	L40.51	Distal interphalangeal psoriatic arthropathy
	L40.52	Psoriatic arthritis mutilans
	L40.53	Psoriatic spondylitis
	L40.59	Other psoriatic arthropathy

Disease	Possible <i>ICD-10-CM</i> code	Descriptor
AS	M45.0	Ankylosing spondylitis of multiple sites in spine
	M45.1	Ankylosing spondylitis of occipito-atlanto-axial region
	M45.2	Ankylosing spondylitis of cervical region
	M45.3	Ankylosing spondylitis of cervicothoracic region
	M45.4	Ankylosing spondylitis of thoracic region
	M45.5	Ankylosing spondylitis of thoracolumbar region
	M45.6	Ankylosing spondylitis of lumbar region
	M45.7	Ankylosing spondylitis of lumbosacral region
	M45.8	Ankylosing spondylitis of sacral and sacrococcygeal region
M45.9	Ankylosing spondylitis of unspecified sites in spine*	

Disease	Possible <i>ICD-10-CM</i> code	Descriptor
nr-axSpA	M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine*
	M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region
	M45.A2	Non-radiographic axial spondyloarthritis of cervical region
	M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region
	M45.A4	Non-radiographic axial spondyloarthritis of thoracic region
	M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region
	M45.A6	Non-radiographic axial spondyloarthritis of lumbar region
	M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region
	M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region
	M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine

\*When billing with an unspecified *ICD-10-CM* code, check with payer for applicability.

AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis.

**Reference:** 1. Codify by AAPC. *ICD-10-CM* codes lookup. Accessed July 27, 2023. <https://www.aapc.com/codes/icd-10-codes-range/#:-:text=The%20International%20Classification%20of%20Diseases,external%20causes%20of%20injuries%20>

**Please see Important Safety Information on page 13 and 14. Please see full Prescribing Information, including Medication Guide.**



# Setting of care codes

## Place of Service (POS) codes<sup>1</sup>

**POS** codes are used to indicate the setting in which a service was provided. The Centers for Medicare & Medicaid Services (CMS) maintains a database of POS codes commonly used in the healthcare industry. Below are examples of some common POS codes. Review the full listing of the POS codes on the CMS website and consult your health plan's guidance to determine the correct code for your institution.

Service	Code	Description
Office	11	Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, state or local public health clinic, or intermediate care facility (ICF), where the healthcare professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.
On Campus— Outpatient Hospital	22	A portion of a hospital's main campus, that provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization. (Description change effective January 1, 2016.)
Independent Clinic*	19	A portion of an off-campus, hospital provider-based department, that provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization. (Effective January 1, 2016.)

## Hospital revenue codes<sup>2</sup>

Specific forms, such as **UB-04 (CMS-1450)**, require documentation of revenue codes associated with services provided to patients.

Below are commonly used revenue codes for processing claims for products, such as COSENTYX<sup>®</sup> (secukinumab). This is not an all-inclusive list of revenue codes that could be used, and it is recommended to review individual health plan guidance to determine the appropriate codes for the IV formulation of COSENTYX.

Revenue code	Description
0250	Pharmacy, General
0260	IV (Intravenous) Therapy, General
0510	Clinic, General
0636	Pharmacy, Drugs requiring detailed coding

\*An independent diagnostic testing facility shall not be allowed to bill for any CPT or HCPCS codes that are solely therapeutic.

**References:** **1.** Centers for Medicare & Medicaid Services. Place of service code set. Accessed July 25, 2023. [https://www.cms.gov/medicare/coding/place-of-service-codes/place\\_of\\_service\\_code\\_set\\_June\\_2023](https://www.cms.gov/medicare/coding/place-of-service-codes/place_of_service_code_set_June_2023) **2.** Noridian Healthcare Solutions. Revenue codes. Accessed July 25, 2023. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes>

**Please see Important Safety Information on page 13 and 14. Please see full Prescribing Information, including Medication Guide.**

# Submitting claims: claim filing checklist


After your patient has been administered the IV formulation of COSENTYX<sup>®</sup> (secukinumab), a claim for reimbursement is submitted to their health plan. When submitting a claim, it is a best practice to understand the health plan's specific coding and billing requirements and ensure that the submitted claim is as complete as possible. You may want to reference the following general tips when filing claims for the IV formulation of COSENTYX:

- Use appropriate codes to report the patient's condition, the drugs the patient received, and the services you provided**
  - ▶ ICD-10-CM code
  - ▶ CPT code
  - ▶ HCPCS code
  - ▶ Dosage and strength (if applicable)
  - ▶ Method of administration
  - ▶ NDC number
  
- Attach additional information to the claim if necessary**
  - ▶ Letter of medical necessity
  - ▶ Prescribing Information
  - ▶ Patient notes
  
- Ensure that the appropriate amount of units are billed based on the codes used, especially when using a miscellaneous code
  
- Review claim for accuracy, including patient identification numbers and coding
  
- File claim as soon as possible and within health plan filing time limits
  
- Reconcile claim reports promptly and thoroughly to ensure claims have been appropriately processed and paid
  
- Verify that payment amounts correspond with your public health plan allowables and your private health plan contracts

# Submitting claims: sample forms

## Physician's office: sample CMS-1500 form

The IV formulation of COSENTYX® (secukinumab) and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. A sample CMS-1500 claim for billing the IV formulation of COSENTYX is provided below.<sup>1</sup> The sample claim form provided is only an example. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party health plans for specific information on their coding, coverage, payment policies, and fee schedules.



**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

**Box 19** (Carrier Information): Enter the Drug Name (COSENTYX [(secukinumab)]), Dose Administered (e.g. 175mg), Strength (125mg/5ml per vial), Route of Administration (Infusion), NDC (00078-1168-61). Payer may have varying requirements for data included in Box 19.

**Box 21** (Diagnosis): Indicate diagnosis using appropriate ICD-10-CM code(s).<sup>2</sup>

**Box 24A** (Drug Description): In the non-shaded area, list the date(s) of service. In the shaded area, give a detailed drug description. List the N4 indicator first, then the 11-digit NDC number.<sup>3</sup> Third is the unit of measurement qualifier; the unit quantity is listed at the end. N40078116861ML125.

**Box 24D** (HCPCS Code): Enter the appropriate HCPCS code (eg, J3590) accompanied by the appropriate modifier as required by the health plan, or if needed based on dose given to patient (please see possible modifiers needed for COSENTYX on page 6).<sup>4</sup> Enter the appropriate CPT code (eg, 96413).<sup>5</sup> Please note, policies may vary in regard to specific code requirements.

**Box 24E** (Diagnosis Reference): Enter the diagnosis code reference letter (A or B) as shown in Box 21 to relate the date of service and the procedures performed for the primary diagnosis. If there is more than one diagnosis required with a procedure code, only reference one letter from Box 21.

**Box 24E** (Billing Units): Include the appropriate number of billing units. When using a miscellaneous code, bill 1 unit.

**IMPORTANT INFORMATION:** The coding, coverage, and payment information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for those products and services rendered. Providers should contact third-party health plans for specific information on their coding, coverage, and payment policies. Information and materials are provided to assist healthcare providers, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains, at all times, with the provider.

**References:** 1. Centers for Medicare & Medicaid Services CMS 1500. Accessed July 27, 2023. <https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/Downloads/CMS1500.pdf>  
2. Codify by AAPC. ICD-10-CM codes lookup. Accessed July 27, 2023. <https://www.aapc.com/codes/icd-10-codes-range/#:~:text=The%20International%20Classification%20of%20Diseases%20causes%20of%20injuries%20>  
3. COSENTYX. Prescribing information. Novartis Pharmaceuticals Corp. 4. Centers for Medicare & Medicaid Services. HCPCS quarterly update. Accessed July 27, 2023. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>  
5. Association, American M. CPT Professional 2023 and E/M Companion 2023 Bundle. Available from: AAPC, American Medical Association (AMA), 2022.

# Submitting claims: sample forms (cont)

## Hospital outpatient: sample CMS-1450 (UB-04) form

The IV formulation of COSENTYX® (secukinumab) and the associated services provided in a hospital outpatient setting are billed on the UB-04 claim form or its electronic equivalent. A sample UB-04 form for billing the IV formulation of COSENTYX is provided below.<sup>1</sup> The sample claim form provided below is only an example. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party health plans for specific information on their coding, coverage, payment policies, and fee schedules.

1		2		3a FRY CNTL F 3b NPI 3c REG #		4 - LEVEL OF BILL	
8 PATIENT NAME		9 PATIENT ADDRESS		5 FED TAX NO.		6 STATEMENT COVERED PERIOD FROM THROUGH	
10 BRNCD		11 ADRS		12 DATE		13 COLLECTION CODES	
14 OCCURRENCE DATE		15 OCCURRENCE DATE		16 OCCURRENCE DATE		17 OCCURRENCE DATE	
18		19		20		21	
22		23		24		25	
26		27		28		29	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834		835		836		837	
838		839		840		841	
842		843		844		845	
846		847		848		849	
850		851		852		853	
854		855		856		857	
858		859		860		861	
862		863		864		865	
866		867		868		869	
870		871		872		873	
874		875		876		877	
87							



## Indications & Important Safety Information

### INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

#### WARNINGS AND PRECAUTIONS

##### Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo-controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose-dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

##### Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

## Indications & Important Safety Information (cont)

### WARNINGS AND PRECAUTIONS (cont)

#### Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn's Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn's disease [COSENTYX is not approved for the treatment of Crohn's disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

#### Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

#### Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready<sup>®</sup> pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

#### Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

### MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.



# Glossary

**CMS-1450 (UB-04) form:** Created by the Centers for Medicare & Medicaid Services (CMS), this form is used by healthcare professionals to bill claims for hospital outpatient services.

**CMS-1500 form:** Created by CMS, this form is used by healthcare professionals to bill claims for in-office patient services.

**Current Procedural Terminology (CPT) code:** Uniform language for coding medical services and procedures to streamline reporting and increase accuracy and efficiency.

**Healthcare Common Procedure Coding System (HCPCS):** Identifies the items and services included within certain designated health services (DHS) categories or that may qualify for certain exceptions.

**International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code:** A system used by physicians to classify and code all diagnoses, symptoms, and procedures for claims processing.

**National Drug Code (NDC):** Universal product identifier with a unique set of numbers used for human drugs in the US.

**Place of Service codes:** Also referred to as a Site of Care code, this is a 2-digit code on healthcare professional claims to indicate the setting in which a service was provided. CMS maintains these codes used throughout the healthcare industry.

**Site of Care codes:** Also referred to as a Place of Service code, this is a 2-digit code on healthcare professional claims to indicate the setting in which a service was provided. CMS maintains these codes used throughout the healthcare industry.

**Setting of Service:** Where a drug is administered by a healthcare professional, which affects coding and billing requirements.

# COSENTYX<sup>®</sup> Connect Support Services

Designed to make onboarding seamless and efficient for patients and HCPs



## Benefits Verification

### Investigate coverage obstacles

- Obstacles may include lack of coverage, prior authorization (PA) denial, and step therapy

### Facilitate PA process

- Initiate PA requests or letters of appeal through the provider or support the provider to follow up directly regarding the PA status
- Many payers will allow up to 3 levels of appeal of PA denials



## Savings Options

### As little as \$0 Co-Pay\* Offer for eligible,<sup>†</sup> privately insured patients

- Help patients with the cost of **both** the IV formulation of COSENTYX<sup>®</sup> (secukinumab) and drug administration\*
- You can get patients started using the COSENTYX<sup>®</sup> (secukinumab) Start Form or by signing them up in the Co-Pay Portal
- Once the Explanation of Benefits has been received, you can submit a co-pay claim electronically or by fax

\*See Co-Pay Terms & Conditions below. <sup>†</sup>Certain payers have carve-outs that restrict utilization of manufacturer support programs.



## Acquisition Support

### Guidance on appropriate distributors and specialty pharmacies

- Help practices understand the authorized distributors available to order the IV formulation of COSENTYX
- COSENTYX<sup>®</sup> Connect can also determine if there are any specialty pharmacy requirements



## Billing & Coding Support

### Support with understanding the relevant reimbursement codes for the IV formulation of COSENTYX

- Our team is here to help your practice understand the appropriate codes
- Our Billing & Coding Guide also provides a comprehensive overview of the available codes
- HCPs should contact third-party health plans for specific information on their coding, coverage, and payment policies

Get your patients started on the IV formulation of COSENTYX. Visit the Co-Pay Portal to enroll your patients at [COSENTYX.opushealth.com](https://www.cosentyx.opushealth.com) or Patients can sign up for the co-pay program directly by calling us at 1-844-COSENTYX (1-844-267-3689).



Click to Download the [Start Form](#)

\*Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details. The information herein is provided for educational purposes only. Novartis cannot guarantee health plan coverage or reimbursement. Coverage and reimbursement may vary significantly by plan, patient, and setting of care. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

COSENTYX and the COSENTYX logo are registered trademarks of Novartis AG.